Tumorigenesis is a major hidden danger to human health, with over nine million people worldwide dying from tumors annually. About two-thirds of tumors are caused by persistent infection with oncogenic viruses. Since the human carcinogenic Epstein-Barr ...
Hepatocellular carcinoma (HCC) is one of the most frequent solid tumors worldwide and represents the third cause of mortality among deaths from cancer. It has been extensively studied in terms of genetic alteration in the last 10 years and our knowledge ...
Evaluation of: Yeo W, Mo FK, Chan SL et al.: Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 45 (6), 1382–1389 (2007). HBV infection is a global health problem that causes a wide spectrum of clinical ...
Occult HCV and HBV infections are recently identified entities whose existence became evident when nucleic acid amplification assays of enhanced sensitivity were employed for the detection of viral genomes and their replicative intermediates. These long-...
Notwithstanding the medical importance of the HBV infection, our understanding of how this pathogen enters hepatocytes is incomplete. This reflects a long-lasting dependence of in vitro infection studies solely on primary human hepatocytes, which are ...
Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV) and HCV or influenza virus. ...
Viral fusion, the mechanism by which viruses gain entry into the host cell, is a key step in the replication cycle and an important new target in antiviral therapy and vaccine strategies owing to the conservation of the envelope domains involved and their ...
Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum. The antiviral activity of nitazoxanide was discovered by serendipity in patients with AIDS who were treated for cryptosporidial diarrhea and had HBV ...
An increasing number of people are chronically infected with HIV and HCV, and/or HBV owing to shared routes of transmission. With the advent of HAART, liver disease secondary to hepatitis co-infections has emerged as a leading cause of morbidity and ...
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral ...
Chronic HBV infection remains an important public health problem and currently licensed therapies rarely prevent complications of viral persistence. Silencing HBV gene expression using gene therapy, particularly with exogenous activators of RNAi, holds ...
Aim: To analyze clinical significance of preoperative liver stiffness measurement (LSM) by FibroScan in postcurative resection hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). Patients & methods: A total of 263 patients underwent ...
Background: A systemic review of the survival benefit of immune checkpoint inhibitors (ICIs) in phase III hepatocellular carcinoma (HCC) trials was conducted. Methods: Meta-analyses were performed with the generic inverse-variance method with a fixed-...
Background: The mutations in preS1 of a large envelop protein of HBV may have profound implications in HBV receptor binding to hepatocytes and subsequent entry of the virus into host cells. Aims: This study aimed to identify the mutations in preS1 region ...
Telbivudine (LdT) is an antiviral agent currently used in the treatment of chronic hepatitis B virus, which was first approved by the US FDA in 2006. The safety of LdT is of great importance for patients that receive long-term treatment for this ...
Aim: Isolated hepatitis B core antibodies (aHBc)-only pattern complicates the diagnosis of HBV infections. We evaluated neopterin and sCD14 levels in HBV infections. Methods: aHBc-only (n: 102), healthy control (healthy control group [HCG], n: 100), and ...
Aim: The aim of this study was to determine the overall prevalence of hepatitis B surface antigen (HBsAg) among hemodialysis patients reported from the Eastern Mediterranean Regional Office of the WHO (EMRO) countries and the Middle East. Methods: ...